{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:41:30Z","timestamp":1776274890128,"version":"3.50.1"},"reference-count":55,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2021.12473","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T08:14:59Z","timestamp":1610957699000},"source":"Crossref","is-referenced-by-count":9,"title":["Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma"],"prefix":"10.3892","volume":"21","author":[{"given":"Youngji","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Suehara","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo 113-8431, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kubota","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Tanzawa","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Nakatani","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Nakatsura","sequence":"additional","affiliation":[{"name":"Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kawai","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo 113-8431, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehisa","family":"Kitano","sequence":"additional","affiliation":[{"name":"Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"key20220302134253_b1-ol-0-0-12473","first-page":"64","article-title":"WHO classification of tumours of soft tissue and bone 2013: The main changes compared to the 3rd edition","volume":"50","author":"Zambo","year":"2014","journal-title":"Cesk Patol"},{"key":"key20220302134253_b2-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ejca.2013.10.002","article-title":"Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study","volume":"50","author":"Gelderblom","year":"2014","journal-title":"Eur J Cancer"},{"key":"key20220302134253_b3-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ijc.24320","article-title":"International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons","volume":"125","author":"Mirabello","year":"2009","journal-title":"Int J Cancer"},{"key":"key20220302134253_b4-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPH.0b013e31816e22f3","article-title":"Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data","volume":"30","author":"Esiashvili","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"key20220302134253_b5-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.2003.08.165","article-title":"Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651","volume":"21","author":"Goorin","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20220302134253_b6-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.1990.8.10.1664","article-title":"Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study","volume":"8","author":"Nesbit","year":"1990","journal-title":"J Clin Oncol"},{"key":"key20220302134253_b7-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","article-title":"Advanced chondrosarcomas: Role of chemotherapy and survival","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann Oncol"},{"key":"key20220302134253_b8-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.nec.2015.03.012","article-title":"Chordomas: A review","volume":"26","author":"George","year":"2015","journal-title":"Neurosurg Clin N Am"},{"key":"key20220302134253_b9-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J Clin Invest"},{"key":"key20220302134253_b10-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20220302134253_b11-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1440-1711.1999.00795.x","article-title":"The role of CTLA-4 in the regulation of T cell immune responses","volume":"77","author":"McCoy","year":"1999","journal-title":"Immunol Cell Biol"},{"key":"key20220302134253_b12-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","article-title":"PD-1: An inhibitory immunoreceptor involved in peripheral tolerance","volume":"22","author":"Nishimura","year":"2001","journal-title":"Trends Immunol"},{"key":"key20220302134253_b13-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/cas.12986","article-title":"Lymphocyte-activation gene-3, an important immune checkpoint in cancer","volume":"107","author":"He","year":"2016","journal-title":"Cancer Sci"},{"key":"key20220302134253_b14-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1080\/21645515.2015.1056953","article-title":"Tim-3 and Tim-4 as the potential targets for antitumor therapy","volume":"11","author":"Cheng","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"key20220302134253_b15-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4161\/self.1.3.12968","article-title":"CD28 co-signaling in the adaptive immune response","volume":"1","author":"Riha","year":"2010","journal-title":"Self Nonself"},{"key":"key20220302134253_b16-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1615\/CritRevImmunol.v29.i3.10","article-title":"The role of OX40-mediated co-stimulation in T-cell activation and survival","volume":"29","author":"Redmond","year":"2009","journal-title":"Crit Rev Immunol"},{"key":"key20220302134253_b17-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1158\/0008-5472.CAN-10-1733","article-title":"Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes","volume":"71","author":"Palaz\u00f3n","year":"2011","journal-title":"Cancer Res"},{"key":"key20220302134253_b18-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/35051100","article-title":"ICOS co-stimulatory receptor is essential for T-cell activation and function","volume":"409","author":"Dong","year":"2001","journal-title":"Nature"},{"key":"key20220302134253_b19-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/1521-4141(200104)31:4<1076::AID-IMMU1076>3.0.CO;2-Y","article-title":"Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin","volume":"31","author":"Pende","year":"2001","journal-title":"Eur J Immunol"},{"key":"key20220302134253_b20-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20220302134253_b21-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20220302134253_b22-ol-0-0-12473","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0939-1","article-title":"A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies","author":"Armand","year":"2020","journal-title":"Leukemia"},{"key":"key20220302134253_b23-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"key20220302134253_b24-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"73","DOI":"10.14712\/18059694.2016.63","article-title":"Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders","volume":"53","author":"Kond\u0115lkov\u00e1","year":"2010","journal-title":"Acta Med (Hradec Kralove)"},{"key":"key20220302134253_b25-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1158\/2326-6066.CIR-15-0298","article-title":"Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients","volume":"4","author":"Tada","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"key20220302134253_b26-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2326-6066.CIR-14-0013","article-title":"Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes","volume":"2","author":"Kitano","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"key20220302134253_b27-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.3892\/ol.2017.6305","article-title":"Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer","volume":"14","author":"Gonda","year":"2017","journal-title":"Oncol Lett"},{"key":"key20220302134253_b28-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00262-013-1447-1","article-title":"Increase in CD14+HLA-DR\u2212\/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis","volume":"62","author":"Arihara","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"key20220302134253_b29-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jim.2012.04.004","article-title":"Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples","volume":"381","author":"Kotsakis","year":"2012","journal-title":"J Immunol Methods"},{"key":"key20220302134253_b30-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20220302134253_b31-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00262-011-1028-0","article-title":"Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13","volume":"60","author":"Gabitass","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"key20220302134253_b32-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"659294","DOI":"10.1155\/2014\/659294","article-title":"A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic\/predictive factor in untreated non-small lung cancer patients","volume":"2014","author":"Vetsika","year":"2014","journal-title":"J Immunol Res"},{"key":"key20220302134253_b33-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"95083","DOI":"10.18632\/oncotarget.18297","article-title":"The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy","volume":"8","author":"Shoji","year":"2017","journal-title":"Oncotarget"},{"key":"key20220302134253_b34-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2051-1426-1-10","article-title":"Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer","volume":"1","author":"Wesolowski","year":"2013","journal-title":"J Immunother Cancer"},{"key":"key20220302134253_b35-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1136\/gutjnl-2017-314032","article-title":"Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy","volume":"67","author":"Zhou","year":"2018","journal-title":"Gut"},{"key":"key20220302134253_b36-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-15-3104","article-title":"Clinical significance of circulating CD33+CD11b+HLA-DR\u2212 myeloid cells in patients with stage IV melanoma treated with Ipilimumab","volume":"22","author":"Sade-Feldman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20220302134253_b37-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"key":"key20220302134253_b38-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12026-014-8524-1","article-title":"Regulation of T cell responses by the receptor molecule Tim-3","volume":"59","author":"Gorman","year":"2014","journal-title":"Immunol Res"},{"key":"key20220302134253_b39-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"e58006","DOI":"10.1371\/journal.pone.0058006","article-title":"Tim-3 expression defines regulatory T cells in human tumors","volume":"8","author":"Yan","year":"2013","journal-title":"PLoS One"},{"key":"key20220302134253_b40-ol-0-0-12473","first-page":"1","article-title":"Upregulation of TIM-3 and PD-1 on CD4+ and CD8+ T cells associated with dysfunction of cell-mediated immunity after colorectal cancer operation","volume":"55","author":"Arai","year":"2012","journal-title":"Yonago Acta Med"},{"key":"key20220302134253_b41-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.coi.2011.12.005","article-title":"Tim-3, a negative regulator of anti-tumor immunity","volume":"24","author":"Anderson","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"key20220302134253_b42-ol-0-0-12473","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317715643","article-title":"Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma","author":"Ge","year":"2017","journal-title":"Tumour Biol"},{"key":"key20220302134253_b43-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1309\/AJCP9Q6OVLVSHTMY","article-title":"Ectopic expression of TIM-3 in lung cancers: A potential independent prognostic factor for patients with NSCLC","volume":"137","author":"Zhuang","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"key20220302134253_b44-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.humpath.2010.04.005","article-title":"The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms","volume":"41","author":"Dorfman","year":"2010","journal-title":"Hum Pathol"},{"key":"key20220302134253_b45-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J Clin Invest"},{"key":"key20220302134253_b46-ol-0-0-12473","doi-asserted-by":"publisher","DOI":"10.4238\/gmr.15037844","article-title":"Tim-3 facilitates osteosarcoma proliferation and metastasis through the NF-\u03baB pathway and epithelial-mesenchymal transition","author":"Feng","year":"2016","journal-title":"Genet Mol Res"},{"key":"key20220302134253_b47-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"key":"key20220302134253_b48-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","article-title":"Regulation of ligands for the NKG2D activating receptor","volume":"31","author":"Raulet","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"key20220302134253_b49-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1007\/s00018-011-0797-0","article-title":"Regulation of immune cell function and differentiation by the NKG2D receptor","volume":"68","author":"Zafirova","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"key20220302134253_b50-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"42007","DOI":"10.18632\/oncotarget.14917","article-title":"Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"key20220302134253_b51-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1186\/1471-2407-14-957","article-title":"MICA\/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer","volume":"14","author":"Cho","year":"2014","journal-title":"BMC Cancer"},{"key":"key20220302134253_b52-ol-0-0-12473","first-page":"11","article-title":"Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer","volume":"12","author":"Chen","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"key20220302134253_b53-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"key20220302134253_b54-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.coi.2018.03.009","article-title":"Plasticity of myeloid-derived suppressor cells in cancer","volume":"51","author":"Tcyganov","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"key20220302134253_b55-ol-0-0-12473","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:44:55Z","timestamp":1646221495000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2021.12473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,1,18]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2021.12473","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]},"article-number":"212"}}